查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632660

全球免疫療法藥物市場：市場規模、佔有率和趨勢分析（按藥物類型、適應症和地區）、按細分市場預測（2025-2030 年）

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

免疫療法市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，全球免疫療法市場規模預計到 2030 年將達到 5,772 億美元，2025 年至 2030 年的複合年成長率為 13.6%。

推動該產業豐厚成長的關鍵因素包括人們對癌症、自體免疫疾病、發炎性疾病和感染疾病等慢性疾病的認知不斷提高，以及政府對藥品核准的支持政策。標靶治療在治療慢性病方面的應用日益廣泛，這引發了人們對免疫療法藥物的興趣，預計將在預測期內推動該行業的發展。

例如，2022年5月，Astra Zeneca和第一三共的Enhertu（曲妥珠單抗）在美國獲得核准，用於治療HER2陽性乳癌。其他標靶免疫治療藥物包括Kadcyla (曲妥珠單抗 emtansine) 和TECENTRIQ (Atezolizumab)。 2022 年 6 月，羅氏公司獲得歐盟核准將TECENTRIQ用於 NSCLC 的輔助治療。此外，中低收入國家的醫療保健基礎設施發展以及主要企業加強研發力度預計將促進該產業的發展。例如，2021年12月，諾華公司與百濟神州有限公司合作研發osiperlimab (BGB-A1217)，擴大了其免疫腫瘤學研發活動。

2021年8月，輝瑞宣布了治療斑禿的藥物利脫髮症替尼2b/3期臨床試驗的積極結果。此外，全球癌症發生率的增加預計將推動對免疫療法藥物的需求。據Globocan報道，預計2020年將診斷出1,930萬例新癌症病例。此外，根據歐洲腫瘤內科學會的數據，預計2020年至2040年間歐洲癌症發生率將增加21%。因此，各種用於治療癌症的免疫療法藥物的核准預計將促進該行業的成長。

免疫療法市場：概覽

  • 2024 年單株抗體領域佔有最大佔有率，為 76.2%。這一成長得益於治療性單株抗體研發的增加和政府的支持措施。
  • 這一成長歸因於對心血管疾病、呼吸系統疾病和自體免疫疾病等各種慢性疾病的生技藥品治療的高需求。
  • 由於全球癌症發生率的增加以及中低收入國家醫療保健基礎設施的改善，腫瘤學領域佔據市場主導地位，到 2024 年將佔收入的 91.4%。
  • 北美免疫療法市場佔據全球市場主導地位，2024 年的營收佔有率為 49.9%。
  • 這是由於該地區免疫療法的採用日益廣泛、支持性報銷政策以及醫療保健支出不斷增加。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章 免疫療法市場：變數、趨勢與範圍

  • 市場概況/相關展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 免疫療法市場：分析工具
    • 波特五力分析
    • PESTEL 分析

第 4 章 免疫治療藥物市場：按藥物類型估計和趨勢分析

  • 按藥物類型分類的市場佔有率（2024 年和 2030 年）
  • 藥物類型儀表板
  • 依藥物類型分類的市場規模預測及趨勢分析（2018-2030年）
  • 單株抗體
  • 免疫調節劑
  • 疫苗

第 5 章免疫治療藥物市場：按適應症的估計和趨勢分析

  • 各適應症市場佔有率（2024 年及 2030 年）
  • 指示儀錶板
  • 市場規模預測及趨勢分析（2018-2030）
  • 癌症
  • 自體免疫疾病
  • 感染疾病
  • 其他

第6章 免疫治療藥物市場：按地區估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Amgen Inc.
    • Novartis AG
    • AbbVie Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • AstraZeneca
    • GSK plc.
    • Sanofi
    • Bayer AG
Product Code: GVR-4-68039-961-5

Immunotherapy Drugs Market Growth & Trends:

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights:

  • The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
  • The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
  • The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
  • The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
  • This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunotherapy Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 Canada Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 9 Mexico Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 10 Europe Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 11 Europe Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 12 Germany Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 13 UK Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 14 France Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Italy Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 16 Spain Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 17 Sweden Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Denmark Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 19 Norway Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 22 China Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 23 Japan Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 India Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 25 South Korea Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Australia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 28 Latin America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 29 Latin America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Brazil Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 31 Argentina Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 34 South Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 UAE Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Immunotherapy drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Immunotherapy drugs market dynamics
  • Fig. 12 Immunotherapy drugs market: Porter's five forces analysis
  • Fig. 13 Immunotherapy drugs market: PESTLE analysis
  • Fig. 14 Immunotherapy drugs market: Drug type segment dashboard
  • Fig. 15 Immunotherapy drugs market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Monoclonal antibodies market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunomodulator market, 2018 - 2030 (USD Million)
  • Fig. 18 Vaccine market, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy drugs market: Indication segment dashboard
  • Fig. 20 Immunotherapy drugs market: Indication market share analysis, 2024 & 2030
  • Fig. 21 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Autoimmune diseases market, 2018 - 2030 (USD Million)
  • Fig. 23 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunotherapy drugs market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina immunotherapy drugs market, 2018 - 2030 (USD Million
  • Fig. 69 MEA immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework